Invitae

With panel sequencing data for more than 143,000 individuals, researchers characterized intragenic copy number variants in hundreds of monogenic disease genes.

Though the Dow, the Nasdaq, and the Nasdaq Biotechnology Index all rose in May, they were outperformed by the GenomeWeb Index.

Based on the growth in test volume and revenue, the company increased its volume and revenue guidance for the year.

The program is open to anyone in the US or in Puerto Rico who is suspected of having SMA or needs confirmation of the disease via genetic testing.

Only three out of 10 sequencing workflows detected all variants in a synthetic reference sample, according to a study presented at ACMG.

The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.

The firm increased the number of shares it was offering after its stock price fell sharply this week.

JP Morgan Securities and Cowen and Company are the joint book-running managers for the offering, while William Blair is the lead manager.

As part of Invitae's network, patients can build datasets tracking their experiences with rare conditions and make the deidentified data available for research.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.